Review abstract
Nature Chemical Biology 4, 682 - 690 (2008)
Published online: 20 October 2008 | doi:10.1038/nchembio.118
Network pharmacology: the next paradigm in drug discovery
Andrew L Hopkins1
Abstract
The dominant paradigm in drug discovery is the concept of designing maximally selective ligands to act on individual drug targets. However, many effective drugs act via modulation of multiple proteins rather than single targets. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical efficacy. This new appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development—efficacy and toxicity. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets. However, the rational design of polypharmacology faces considerable challenges in the need for new methods to validate target combinations and optimize multiple structure-activity relationships while maintaining drug-like properties. Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacology.
- Division of Biological Chemistry and Drug Discovery, College of Life Science, University of Dundee, Dow Street, Dundee DD1 3DF, UK.
Correspondence to: Andrew L Hopkins1 e-mail: a.hopkins@dundee.ac.uk
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Protein promiscuity and its implications for biotechnologyNature Biotechnology Research (01 Feb 2009)
Protein promiscuity and its implications for biotechnologyNature Biotechnology Research (01 Feb 2009)
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinasesNature Chemical Biology Article (01 Nov 2008)
See all 5 matches for Research
